Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

MacroGenics And Lilly Achieve Targeted Patient Enrollment In PROTEGE, A Global Phase 2/3 Clinical Trial Of Teplizumab In Type 1 Diabetes
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.
generic viagra online
The Downside Of Microtubule Stability - Study Shows Stalled Microtubules Might Be Responsible For Some Cases Of Charcot-Marie-Tooth Disease
Stalled microtubules might be responsible for some cases of the neurological disorder Charcot-Marie-Tooth (CMT) disease, Tanabe and Takei report in the June 15, 2009 issue of the Journal of Cell Biology. A mutant protein makes the microtubules too stable to perform their jobs, the researchers find.
plastic surgery before after
News of the day
BSD Receives FDA Humanitarian Use Designation For The BSD-2000 Hyperthermia System
BSD Medical Corporation (NASDAQ:BSDM) announced that the U.S. Food and Drug Administration (FDA) has granted Humanitarian Use Device (HUD) designation for the company"s BSD-2000 Hyperthermia System for use in conjunction with radiation therapy for the treatment of cervical carcinoma patients who are ineligible for chemotherapy. This is the first of the two steps required to obtain Humanitarian Device Exemption (HDE) marketing approval, which requires BSD Medical to demonstrate the device"s safety and probable benefit in treating a disease or condition that affects fewer than 4,000 individuals in the United States per year. Now that FDA has granted the Humanitarian Use Designation for the BSD-2000, which confirms that the intended use population is fewer than 4,000 patients per year, BSD can file an HDE submission with the FDA. FDA has 75 days from the date of receipt of the HDE submission to grant or deny an HDE application. This period includes a 30-day filing period during which FDA determines whether the HDE application is sufficiently complete to permit substantive review. During this review, FDA may refine the indications for use which received HUD designation to finalize the indications for use for which HDE approval will be granted. This decision will be based on the data that are available to support the device"s HDE application. The company believes that the data previously submitted to FDA and reviewed by the agency in the company"s pending PMA application can be used to support the HDE approval, and that this previous review may expedite marketing approval for the BSD-2000.
Mental Health

Free Mammograms Available Through Minnesota Department Of Health - Newly Enrolled Women Will Also Receive A $20 Bonus

The Minnesota Department of Health (MDH) will offer free mammograms through a televised phone bank on FOX 9 KMSP-TV in Minneapolis on Thursday, June 25, 2009. The phone bank will air during the 5 p.m., 5:30 p.m., 9 p.m. and 10 p.m. newscasts. The mammograms are offered through the Sage Screening Program, a state and federally funded program that provides free breast and cervical cancer screenings to uninsured and underinsured women age 40 and older. Newly enrolled women in the program will also receive $20 for being screened, which has been shown to increase screening rates. Messages stressing the importance of detecting breast cancer early and encouraging women to take advantage of the screening program will also run throughout the campaign. MDH"s toll-free number, 1-888-6-HEALTH will be answered from 8 a.m. to 10:35 p.m. on June 25 and 8 a.m. - 5 p.m. all other weekdays. Voice messages can be left anytime outside of these hours. Through this event, MDH hopes to make more women in Minnesota aware of this free program. "We think many women are not receiving these life-saving screening tests because they have no health insurance or their insurance has deductibles or co-payments they cannot meet. Sage can help," said Jonathan Slater, chief of Cancer Control at MDH. Sage has a network of more than 400 local health care providers statewide, and has served nearly 114,000 women since 1991. Approximately 1,400 women have been diagnosed and treated for breast and cervical cancer through the Sage program. This year, it is estimated that 3,500 Minnesotan women will be diagnosed with breast cancer and approximately 650 Minnesota women will die from the disease. Annual mammography has been reported to reduce breast cancer deaths in women age 40 and older by detecting the disease in its earliest stages when it is most easily treated. Women seeking eligibility information about the free mammography program-or women who want to make an appointment for a free mammogram-should call Sage at 1-888-6-HEALTH (1-888-643-2584). Women living in neighboring states or whose incomes exceed Sage"s guidelines, should call the American Cancer Society at 1-800-227-2345 to learn of other free and low-cost programs. For more information, visit http://www.MNSage.com. Minnesota Department of Health


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009